We are live on
!
Find out more
JBIO
Jade Biosciences
JBIO
JBIO
55 hedge funds and large institutions have $434M invested in Jade Biosciences in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more funds holding
Funds holding: 49 → 55 (+6)
10% more capital invested
Capital invested by funds: $396M → $434M (+$38.7M)
0.14% more ownership
Funds ownership: 3.02% → 3.15% (+0.14%)
Holders
55
Holders Change
+6
Holders Change %
+12.24%
% of All Funds
0.95%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
10
Increased
20
Reduced
17
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 2 |
O
OrbiMed
New York
|
+$6.03M |
| 3 |
VA
VR Adviser
New York
|
+$4.64M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.81M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.86M |
